通过准c-Met信号通路,crizotinib对骨髓瘤细胞的抗癌作用
Tao Jia1, Mengmeng Cai2, Zengkun Wang3
1The Second Affiliated Hospital of Harbin Medical University, Harbin, China. jiaraoque19770912@163.com.
Cellular and molecular biology (Noisy-le-Grand, France)
|August 12, 2023
概括
克里佐替尼 (crizotinib) 是一种针对c-Met的药物,有效地抑制骨髓瘤 (OS) 细胞的增殖和转移. 这项研究证明了crizotinib.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在骨髓瘤中,C-Met受体和肝细胞生长因子 (HGF) 过度表达,这表明它们在瘤发育中的作用.
- 准c-Met/HGF通路为骨髓瘤提供了一个潜在的治疗策略.
研究的目的:
- 为了研究c-Met向药物crizotinib对骨髓瘤 (OS) 细胞的抗癌作用.
- 评估crizotinib对OS细胞增殖,细胞亡,细胞循环,迁移和入侵的影响.
- 分析crizotinib对OS细胞中c-Met信号通路的影响.
主要方法:
- 骨髓瘤细胞系 (SaOS2,MG-63,MNNG) 用不同度的crizotinib进行治疗.
- 用CCK8试验评估细胞增殖.
- 在MG-63细胞中评估了细胞亡,细胞循环,迁移和入侵.
- 西方涂抹被用来检测c-Met信号通路蛋白质表达.
主要成果:
- 克里佐替尼 (crizotinib) 显示出对骨髓瘤细胞增殖的剂量依赖抑制.
- 克里佐替尼显著增加了癌细胞的亡,并改变了细胞周期分布 (增加G0/G1,减少S阶段).
- 克里佐替尼抑制了骨髓瘤细胞迁移和入侵,并降低了c-Met/Gab1/STAT5通路的调节.
结论:
- 克里佐替尼在体外对骨髓瘤细胞表现出显著的抗癌活性.
- c-Met信号通路是骨髓瘤治疗的可行治疗标.
- 克里佐替尼 (crizotinib) 显示出作为一种潜在的治疗剂在骨髓瘤中临床应用的前景.
更多相关视频
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
9.4K
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
7.2K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
